JPMorgan Chase & Co. has announced the filing of a free writing prospectus for a new offering of structured investment notes. These notes are linked to major U.S. stock indices, including the Nasdaq-100, Russell 2000, and S&P 500. This move is significant as it showcases the bank's strategy to provide diverse investment opportunities to its clients.
The structured notes will have a minimum denomination of $1,000 and are designed to offer a contingent interest rate of at least 10.50% per annum. The pricing date for these notes is set for November 30, 2026, with a maturity date of June 2, 2028. The notes will also feature quarterly autocall review dates after an initial six-month non-call period.
The offering is expected to attract investors looking for potentially high returns linked to the performance of these major indices. However, the notes carry risks, including the possibility of losing principal if the underlying indices perform poorly. Investors should be aware that payments on the notes are subject to the credit risk of JPMorgan Chase Financial Company LLC, the issuer of the notes, and JPMorgan Chase & Co., the guarantor.
This filing, accession number 0001918704-26-035083, reflects JPMorgan's ongoing efforts to innovate within the structured investment space, potentially influencing the broader national commercial banks sector. Competitors may respond with similar offerings to capture market interest.
Details regarding the specific risks associated with these notes are outlined in the prospectus, which investors are encouraged to review before making any investment decisions.
As for the next steps, the filing does not specify any further actions or upcoming events related to this offering.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










